Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3595787 | 1.00 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3L3MBTL1KDM4E | |
| SCHEMBL1863059 | 0.82 | L3MBTL1 (0.31) | SLC6A2SLC6A4SLC6A3L3MBTL1 | |
| SCHEMBL1866972 | 0.82 | L3MBTL1 (0.31) | SLC6A2SLC6A4SLC6A3L3MBTL1 | |
| SCHEMBL3599061 | 0.76 | ADRB2 (0.32) | L3MBTL1 | |
| SCHEMBL3595027 | 0.75 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3L3MBTL1KDM4E | |
| SCHEMBL3603986 | 0.75 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3L3MBTL1KDM4E | |
| SCHEMBL1870673 | 0.73 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3L3MBTL1KDM4E | |
| SCHEMBL1859132 | 0.70 | CTSK (0.40) | — | |
| SCHEMBL2496650 | 0.69 | L3MBTL1 (0.33) | L3MBTL1 | |
| SCHEMBL14911218 | 0.67 | ALOX5 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455521-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-7754737-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090018103-A1 | Diaminoalkane Aspartic Protease Inhibitors | VITAE PHARMACEUTICAL, INC (US) | 2009-01-15 | — | — | US | disclosed |
| EP-1807078-A1 | DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006042150-A1 | DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018103-A1 | Diaminoalkane Aspartic Protease Inhibitors | DNPEP, PEPD, ACE | SLC6A2 3389/4885SLC6A4 3809/4885SLC6A3 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.